| Metric | Value ($ M) | Q2 FY26 | Q3 FY25 |
|---|---|---|---|
| Revenue | 1.60 | 37.9% | 4.2% |
| Total Income | 1.60 | 37.9% | 4.2% |
| Expenditure | 64.85 | 25.9% | 22.8% |
| PBT | — | ||
| Net Profit | -56.89 | 28.0% | 29.9% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.64 | 28.9% | 12.3% |
CG Oncology Reports Q3 2026 Financial Results and Provides Business Updates
06 Nov 2026 · 6 Nov, 7:01 pm
Summary
CG Oncology reported its financial results for the third quarter ended September 30, 2026, alongside business updates. The company incurred a net loss of $56.9 million, or $(0.64) per share, for the quarter. Research and Development expenses rose to $39.2 million, while G&A expenses slightly decreased to $23.0 million. The company maintains a strong cash position of $984.5 million, sufficient to fund operations through 2029, and is focused on upcoming clinical milestones including PIVOT-006 topline data and BLA submission.
Key Highlights
- 1
CG Oncology reported a net loss of $56.9 million, or $(0.64) per share, for the third quarter of 2026.
- 2
Research and Development (R&D) expenses increased to $39.2 million for the third quarter of 2026, compared to $27.9 million in the prior year period.
- 3
General and Administrative (G&A) expenses were $23.0 million for the third quarter of 2026, a slight decrease from $23.3 million in the prior year period.
- 4
The company's cash, cash equivalents, and marketable securities stood at $984.5 million as of September 30, 2026, with operations funded through 2029.
- 5
Anticipated milestones include PIVOT-006 Phase 3 topline data in November 2026 and BLA completion for BCG-unresponsive NMIBC in Q4 2026.
Management Comments
Arthur Kuan
We are entering an eventful period for CG Oncology as we look forward to sharing PIVOT-006 topline data this month. As a reminder, PIVOT-006 is the first randomized registrational trial in intermediate-risk and high-grade Ta NMIBC. Additionally, we expect to have 12-month data from both CORE-008 Cohort CX and BOND-003 Cohort P in December, which further strengthens the growing body of evidence for cretostimogene across the NMIBC landscape and supports our goal to address the broadest number of patients. We remain confident in cretostimogene’s potential to become a backbone therapy for patients and to create long-term value for shareholders.
Informational and educational content only. Not investment advice.